



ten23 health® and BD partner to enable supply chain readiness of BD Libertas™ wearable injector as full-service solution

The partnership addresses growing demand for self-administered therapies with a scalable, ready-to-use injector platform.

Basel, Switzerland – January 20, 2026 – ten23 health®, the human-centric and sustainable strategic CDMO partner of choice for the pharmaceutical industry and biotech start-ups today announced a manufacturing collaboration to support the commercialization of the BD Libertas™ wearable injector. The collaboration will offer biopharma companies supply chain readiness of a fully integrated, ready-to-use solution for the subcutaneous delivery of large-volume drugs, helping speed development and reduce risk in complex injectable programs.

The collaboration includes the BD Libertas™ wearable injector with a 5 ml or 10 ml BD glass cartridge, supported by ten23 health's process development, aseptic filling, assembly, and quality control services. This setup enables pharmaceutical partners to leverage the BD Libertas™ wearable Injector platform and ten23 development and manufacturing services to bring high-volume subcutaneous treatments to the clinic and market, maintaining flexibility and adequate patient usability.

ten23's recently announced Line 0 will enable Pharmaceutical Customers to test cartridge compatibility, perform stability studies, and optimize filling and stopper setting processes under fully representative conditions, without the delays or costs of GMP production. This enables a faster and more informed path to scale-up.

The BD Libertas™ Wearable Injector offers a ready-to-use, wearable injector for subcutaneous administration of high-dose biologics—enabling pharma to transition biologics from IV to SC delivery with potential for a positive patient experience. By combining BD platform technology with ten23 integrated services, BD and ten23 health aim to enable supply chain readiness to support commercialization and support smoother regulatory pathways.



“Enabling successful patient treatment on behalf of our customers is a key priority for ten23. Based on the already successful collaboration of ten23 with BD for the BD iDFill™ solution (RFID-enabled PFS/containers), we are happy to expand our collaboration to also include BD Libertas™ Wearable Injector platform. Our unique offerings and experiences with a range of devices make ten23 an ideal partner for any SC delivery options”, says Prof. Dr. Hanns-Christian Mahler, Chief Enablement Officer at ten23 health.

Disclaimer

BD Libertas™ Wearable Injector is a product in development; some statements are forward looking and are subject to a variety of risks and uncertainties. BD Libertas Wearable Injector is a device component intended for drug-device combination products and not subject to FDA 510(k) clearance or separate EU CE mark certification. The BD iDFill™ solution referenced above is in development; some statements are forward-looking and subject to a variety of risks and uncertainties. Any actual solution placed on the market may differ.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.

About ten23 health

ten23 health®, located in Basel and Visp, Switzerland, is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups: we develop, manufacture, and test modern medicines. We support our clients in developing differentiated, stable, usable, and safe injectable treatment options for patients.

ten23 health® combines the latest scientific findings with proven and tested world-class industry and



regulatory expertise to forge new paths for supporting clients. We provide our innovative services in a fair and sustainable manner, respecting people's health and the future of our planet. ten23 health® is a B Corp member and solidly financed through the long-term commitment of 3i Group, an internationally reputable equity partner.

About the company's name

The numeric value for the number of molecules in a sample of one mol is called Avogadro constant and equals $6.022 * 10^{23}$. Gram quantities of material contain the incredible number of 10^{23} atoms, which was an important discovery to understand the composition of matter: The world is built from small units, and not a homogeneous mass.

About 3i Group

3i is an investment company with two complementary businesses, Private Equity and Infrastructure, and invests in mid-market companies headquartered in Europe and North America. 3i's Private Equity team provides investment solutions for growing companies, backing entrepreneurs and management teams of companies with an EV typically between €100m - €500m. 3i backs international growth plans, providing access to its network and expertise to accelerate the growth of companies across the consumer, healthcare, industrial and private label, and services and software industries.

Media contacts:

ten23 health: Mara Willa, mara.willa@ten23.health

3i Group: Kathryn van der Kroft, Kathryn.VanDerKroft@3i.com

